Rule~4.7B

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Ν	ame	of	en	tity

Medibio Limited	(formerly BioProspect Limited)

ABN

58 008 130 336

Quarter ended ("current quarter")

30 June 2015

Consolidated statement of cash flows

		Current quarter	Year to date
Cash flows related to operating activities		\$A'000	(12months)
			\$A'000
1.1	Receipts from customers	-	-
1.2	Payments for (a) staff costs	(159)	(359)
	(b) advertising and marketing	-	-
	(c) research and development	(400)	(400)
	(d) leased assets	-	-
	(e) other working capital	(446)	(2,191)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature		
	received	3	7
1.5	Interest and other costs of finance paid	-	(1)
1.6	Income taxes paid	-	-
1.7	Other (GST & R&D refunds)	164	361
		(838)	(2,583)
	Net operating cash flows		

⁺ See chapter 19 for defined terms.

		Current quarter \$A'000	Year to date (12months) \$A'000
1.8	Net operating cash flows (carried forward)	(838)	(2,583)
	Cash flows related to investing activities		
1.9	Payment for acquisition of:	-	-
	(a) businesses (item 5)	-	-
	(b) equity investments	-	(558)
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other	-	-
		-	(558)
	Net investing cash flows		
1.14	Total operating and investing cash flows	(838)	(3,141)
	Cash flows related to financing activities		
1.15	Proceeds from issues of shares, options, etc.	488	3,258
1.16	Proceeds from sale of forfeited shares	-	5,230
1.17	Proceeds from borrowings		835
1.18	Repayment of borrowings	_	(100)
1.19	Dividends paid		(100)
1.20	Other (Convertible note interest)		
1.20		488	3,993
	Net financing cash flows		
	Net increase (decrease) in cash held	(350)	852
1.21 1.22	Cash at beginning of quarter/year to date Exchange rate adjustments to item 1.20	1,298	96 -
1.23	Cash at end of quarter	948	948

Appendix 4C Page 2 17/12/2010

⁺ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors Payments to related entities of the entity and associates of the related entities

			Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2		20
1.25	Aggregate amount of loans to the parties included in item 1.11		
1.26	Explanation necessary for an understanding of the transactions Directors fees for the quarter		
No	n-cash financing and investing activi	ities	
2.1	Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows		
2.2	Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest		
Financing facilities available Add notes as necessary for an understanding of the position.			
		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

On 6 March 2015 the Shareholders of Medibio Limited at a General Meeting, approved 16 Resolutions including equity consolidation and conversion of debt to equity. Also approved were the acquisition of Invatec Health Pty Ltd and a capital raising of up to \$3 million by the issue of shares at \$0.30. These transactions were finalised 7 April 2015.

A further equity raising (completing the April raising) were finalised on 30 June and announced by an Appendix 3B dated 10 July 2015.

⁺ See chapter 19 for defined terms.

Reconciliation of cash

showr	nciliation of cash at the end of the quarter (as in the consolidated statement of cash flows) to lated items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	214	8
4.2	Deposits at call	734	1,290
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
	Total: cash at end of quarter (item 1.23)	948	1,298

Acquisitions and disposals of business entities

		Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity		
5.2	Place of incorporation or registration		
5.3	Consideration for acquisition or disposal		
5.4	Total net assets		
5.5	Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here: Date: 31 July 2015

(Company secretary)

Print name: Robert Lees

Appendix 4C Page 4 17/12/2010

⁺ See chapter 19 for defined terms.

Notes

- 1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
- 2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
- 3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

⁺ See chapter 19 for defined terms.